Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia

European Journal of Clinical Pharmacology

Volumn 63, Issue 10, 2007, Pages 951-957

  Doki, Kosuke ^a   Homma, Masato ^a   Kuga, Keisuke ^a   Aonuma, Kazutaka ^a   Sakai, Satoshi ^a   Yamaguchi, Iwao ^a   Kohda, Yukinao ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Anti arrhythmic efficacy; CYP2D6; Flecainide; Gender associated difference; Pharmacokinetics

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM ANTAGONIST; CARTEOLOL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FAMOTIDINE; FLECAINIDE; IMIDAPRIL; NADOLOL; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; PRAVASTATIN; QUINAPRIL; RANITIDINE; TICLOPIDINE; VERAPAMIL; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOLTER MONITORING; HUMAN; JAPANESE; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SEX RATIO; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; SUPRAVENTRICULAR TACHYCARDIA;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2D6; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FLECAINIDE; GENOTYPE; HAPLOTYPES; HUMANS; JAPAN; MALE; MIDDLE AGED; MUSCLE PROTEINS; PROMOTER REGIONS (GENETICS); SEX FACTORS; SODIUM CHANNELS; TACHYCARDIA, SUPRAVENTRICULAR; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548546829     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0348-7     Document Type: Article

References (22)

1. Hopson JR, Buxton AE, Rinkenberger RL, Nademanee K, Heilman JM, Kienzle MG (1996) Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group. Am J Cardiol 77:72A-82A
2. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781-788
3. Takada M, Goto T, Kotake T, Saito M, Kawato N, Nakai M, Gunji T, Shibakawa M (2005) Appropriate dosing of antiarrhythmic drugs in Japan requires therapeutic drug monitoring. J Clin Pharm Ther 30:5-12
4. McQuinn RL, Quarfoth GJ, Johnson JD, Banitt EH, Pathre SV, Chang SF, Ober RE, Conard GJ (1984) Biotransformation and elimination of 14C-flecainide acetate in humans. Drug Metab Dispos 12:414-420
5. Conard GJ, Ober RE (1984) Metabolism of flecainide. Am J Cardiol 53:41B-51B
6. Mikus G, Gross AS, Beckmann J, Hertrampf R, Gundert-Remy U, Eichelbaum M (1989) The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. Clin Pharmacol Ther 45:562-567
7. Doki K, Homma M, Kuga K, Kusano K, Watanabe S, Yamaguchi I, Kohda Y (2006) Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia. Eur J Clin Pharmacol 62:919-926
8. Doki K, Homma M, Kuga K, Watanabe S, Yamaguchi I, Kohda Y (2004) Simultaneous determination of serum flecainide and its metabolites by using high performance liquid chromatography. J Pharm Biomed Anal 35:1307-1312
9. Ishiguro A, Kubota T, Soya Y, Sasaki H, Yagyu O, Takarada Y, Iga T (2005) High-throughput detection of multiple genetic polymorphisms influencing drug metabolism with mismatch primers in allele-specific polymerase chain reaction. Anal Biochem 337:256-261
10. Bezzina CR, Shimizu W, Yang P, Koopmann TT, Tanck MW, Miyamoto Y, Kamakura S, Roden DM, Wilde AA (2006) Common sodium channel promoter haplotype in Asian subjects underlies variability in cardiac conduction. Circulation 113:338-344
11. Chimienti M, Cullen MT Jr, Casadei G (1996) Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. Am J Cardiol 77:60A-75A
12. Hellestrand KJ (1996) Efficacy and safety of long-term oral flecainide acetate in patients with responsive supraventricular tachycardia. Am J Cardiol 77:83A-88A
13. Dorian P, Naccarelli GV, Coumel P, Hohnloser SH, Maser MJ (1996) A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia. The Flecainide Multicenter Investigators Group. Am J Cardiol 77:89A-95A
14. Atarashi H, Ogawa S, Inoue H, Hamada C (2007) Dose-response effect of flecainide in patients with symptomatic paroxysmal atrial fibrillation and/or flutter monitored with trans-telephonic electrocardiography: a multicenter, placebo-controlled, double-blind trial. Circ J 71:294-300
15. Homma M, Kuga K, Doki K, Katori K, Yamaguchi I, Sugibayashi K, Kohda Y (2005) Assessment of serum flecainide trough levels in patients with tachyarrhythmia. J Pharm Pharmacol 57:47-51
16. Kroemer HK, Turgeon J, Parker RA, Roden DM (1989) Flecainide enantiomers: disposition in human subjects and electrophysiologic actions in vitro. Clin Pharmacol Ther 46:584-590
17. Holtzman JL, Weeks CE, Kvam DC, Berry DA, Mottonen L, Ekholm BP, Chang SF, Conard GJ (1989) Identification of drug interactions by meta-analysis of premarketing trials: the effect of smoking on the pharmacokinetics and dosage requirements for flecainide acetate. Clin Pharmacol Ther 46:1-8
18. Bebia Z, Buch SC, Wilson JW, Frye RF, Romkes M, Cecchetti A, Chaves-Gnecco D, Branch RA (2004) Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 76:618-627
19. Tanaka E (1999) Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm The 24:339-346
20. Schwartz JB (2003) The influence of sex on pharmacokinetics. Clin Pharmacokinet 42:107-211
21. Thurmann PA, Haack S, Werner U, Szymanski J, Haase G, Drewelow B, Reimann IR, Hippius M, Siegmund W, May K, Hasford J (2006) Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex-dependent. Clin Pharmacol Ther 80:551-553
22. Wyse DG, Hallstrom A, McBride R, Cohen JD, Steinberg JS, Mahmarian J (1991) Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in patients surviving open label titration but not randomized to double-blind therapy. J Am Coll Cardio 18:20-28